Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-clotting drugs yield similar results

27.08.2012
Potential long-term benefit observed for first time in ACS patients

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs – prasugrel and clopidogrel – in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists.

The study also showed no difference in serious bleeding complications.

At the same time, the Duke researchers observed an unexpected reduction in heart attack, stroke and death among patients treated with prasurgrel beyond one year of treatment. The researchers say this potential time-dependent benefit requires further exploration.

The results were presented by the Duke researchers at the European Society of Cardiology Scientific Sessions in Munich, Germany today, and published online in the New England Journal of Medicine.

"If you look at this study as a comparison of two drugs, it doesn't tell the whole story," says E. Magnus Ohman, M.D., a professor of medicine at Duke and chairman of the TRILOGY ACS study. "This is a unique patient population that has never before been studied."

Acute coronary syndrome (ACS) refer to a group of conditions that include heart attacks and chest pain caused by clogged coronary arteries. To date, most trials evaluating anti-clotting drugs for ACS patients have focused on patients who undergo revascularization procedures such as stent implantation with percutaneous coronary intervention and coronary artery bypass surgery to restore blood flow.

Up to 60 percent of ACS patients worldwide undergo revascularization procedures according to published data. The remaining 40 percent are managed solely with drug therapy. These patients are at higher risk for repeated cardiovascular-related events, such as heart attack, stroke, and death.

"Optimizing medical therapy for these patients is extremely important," Ohman says.

Prasugrel and clopidogrel are members of the thienopyridine class of adenosine diphosphate receptor inhibitors that prevent the formation of blood clots in arteries by binding to specific receptors and inhibiting the clumping of platelets.

The efficacy and safety of the two drugs were first compared in a Phase III trial called TRITON that evaluated 13,608 ACS patients who planned to undergo stent implantation. The TRITON study, published in 2007, found that 10 mg of prasugrel was 19 percent more effective in preventing cardiovascular death, nonfatal heart attacks and strokes than clopidogrel. It also found prasurgrel caused a higher incidence of fatal bleeding.

TRILOGY ACS is a Phase III, double-blind, randomized trial that was developed as a follow-up to the TRITON trial.

"We designed our study to see if prasugrel was just as effective in patients who aren't getting coronary stents or coronary bypass surgery," says Ohman.

TRILOGY ACS enrolled 9,326 participants at 966 sites in 52 countries. It compared up to 2.5 years of treatment with prasugrel 10 mg daily vs. clopidogrel 75 mg daily, both in combination with aspirin, in ACS patients who were younger than age 75 years. The prasugrel dose was reduced to 5 mg daily for patients weighing less than 60 kilograms. A secondary analysis also looked at patients who were age 75 years or older who received 5 mg of prasurgrel daily vs. clopidogrel 75 mg daily because TRITON demonstrated an increased risk of major bleeding in these patients when they were treated with prasugrel 10mg daily.

After a median of 17 months of follow up, the primary end point - described as the time to first occurrence of death, heart attack or stoke - occurred in 13.9 percent of patients under age 75 years vs. 16.0 percent of those treated with clopidogrel. This is considered a non-significant difference.

However, a lower risk of recurrent adverse events with prasugrel was observed after 12 months of treatment. "This finding has not been observed in previous studies such as TRITON that evaluated a shorter duration of treatment," said Dr. Ohman. "We believe further exploration of this finding is needed."

The researchers did not observe an increase in severe or life-threatening bleeding complications with prasugrel as seen in the TRITON study. "Because we modified the prasugrel dose for patients with a higher risk of bleeding, we observed that prasugrel is as safe as clopidogrel with long-term treatment," said Dr. Ohman.

Funding: TRILOGY ACS is sponsored by Eli Lilly and Company, and Daiichi Sankyo Co.

Disclosures: Co-authors Drs. E. Magnus Ohman and Matthew Roe report receiving research support and research grants from Eli Lilly & Company, Daiichi Sankyo and other sources. A complete list of all author disclosures is contained in the manuscript.

Debbe Geiger | EurekAlert!
Further information:
http://www.duke.edu

More articles from Health and Medicine:

nachricht Potential seen for tailoring treatment for acute myeloid leukemia
10.12.2018 | University of Washington Health Sciences/UW Medicine

nachricht UC San Diego researchers develop sensors to detect and measure cancer's ability to spread
06.12.2018 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

Im Focus: Substitute for rare earth metal oxides

New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals

Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.

Im Focus: A bit of a stretch... material that thickens as it's pulled

Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.

Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...

Im Focus: The force of the vacuum

Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.

The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

Expert Panel on the Future of HPC in Engineering

03.12.2018 | Event News

 
Latest News

Small but ver­sat­ile; key play­ers in the mar­ine ni­tro­gen cycle can util­ize cy­anate and urea

10.12.2018 | Life Sciences

New method gives microscope a boost in resolution

10.12.2018 | Physics and Astronomy

Carnegie Mellon researchers probe hydrogen bonds using new technique

10.12.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>